BioCentury
ARTICLE | Company News

Sanofi, BioNTech in cancer immunotherapy deal

November 4, 2015 2:15 AM UTC

Sanofi (Euronext:SAN; NYSE:SNY) and BioNTech AG (Mainz, Germany) partnered to discover and develop up to five mRNA-based cancer immunotherapies.

Sanofi will have exclusive, worldwide rights to candidates that emerge from the deal, while BioNTech has an option to co-develop and co-commercialize two candidates in the EU and U.S. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article